Selumetinib is a mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor (MEKi) approved to treat inoperable plexiform neurofibromas and used off-label for low-grade gliomas. Acneiform eruptions are a known complication of MEKi use, and in some cases, may lead to paused, dose-reduced, or discontinued therapy. Isotretinoin has been reported as an effective treatment for acneiform eruptions secondary to targeted therapies, primarily in the adult population. Here we describe a pediatric patient with a severe acneiform eruption secondary to selumetinib who was successfully treated with low-dose isotretinoin when unresponsive to conventional therapies.

中文翻译：

---

使用低剂量异维A酸成功治疗 MEK 抑制剂诱导的痤疮样皮疹儿童

Selumetinib 是一种丝裂原活化蛋白激酶/细胞外信号调节激酶抑制剂 (MEKi)，被批准用于治疗无法手术的丛状神经纤维瘤，并在标签外用于低级别胶质瘤。痤疮样疹是 MEKi 使用的已知并发症，在某些情况下，可能导致暂停、减少剂量或停止治疗。据报道，异维A酸可有效治疗继发于靶向治疗的痤疮样皮疹，主要针对成人人群。在这里，我们描述了一名继发于司美替尼的严重痤疮样皮疹的儿科患者，该患者在对常规疗法无反应时成功地接受了低剂量异维A酸治疗。